查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1923889

鉬-99和Technetium-99m市場按應用、來源、產品類型和最終用戶分類－2026年至2032年全球預測

Molybdenum-99 & Technetium-99m Market by Application, Source, Product Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，鉬-99 和Technetium-99m 市場價值將達到 35.5 億美元，到 2026 年將成長到 37 億美元，到 2032 年將達到 55.1 億美元，複合年成長率為 6.48%。

關鍵市場統計數據
基準年 2025 35.5億美元
預計年份：2026年 37億美元
預測年份 2032 55.1億美元
複合年成長率 (%) 6.48%

權威概述將鉬-99和Technetium-99m定位為現代診斷影像和臨床工作流程中不可或缺且技術複雜的基礎。

鉬-99及其崩壞產物Technetium-99m是現代核醫學的基石，它們支持多種診斷影像檢查，並輔助特定的治療方案。Technetium-99m具有優異的物理性質，例如半衰期短、伽馬射線發射特性理想，使其特別適用於心臟病學、神經病學和腫瘤學中的單光子發射成像。同時，其母體核種鉬-99是實現廣泛臨床應用的主要放射性核種來源。除了臨床診斷之外，這些放射性核種在工業和研究領域也有廣泛的應用。放射性示蹤劑和成像劑可用於材料測試、製程最佳化以及新型放射性藥物的研究。

技術創新、監管改革和供應鏈轉型如何共同重塑診斷放射性核種的生產路徑和臨床工作流程

過去十年間，鉬-99和Technetium-99m生態系統經歷了許多變革，重塑了其生產、分銷和臨床應用模式。技術創新加速了替代生產途徑的採用，例如直接迴旋加速器生產Technetium-99m以及低濃縮非裂變反應器方法，從而降低了對少數老舊研究核子反應爐的依賴，並提高了監管方面的認可度。同時，發生器技術也在不斷發展，柱化學和凝膠配方的改進提高了洗脫效率，減少了鋁滲透，簡化了現場操作，並縮短了臨床團隊的設置時間。

評估2025年關稅對診斷同位素供應鏈的採購、製造投資和臨床連續性的系統性影響

美國將於2025年實施的關稅對鉬-99和Technetium-99m的全球供應鏈產生了多方面的影響，並對籌資策略、生產經濟和臨床營運產生了連鎖反應。這些關稅影響進口的生產材料、產生器組件和成品同位素產品，給依賴跨境供應關係的機構帶來了即時的成本壓力。為此，相關人員在加快採購多元化、優先發展國內生產路線以及重新談判長期採購合約的步伐，以確保在更可預測的總到岸成本框架下供應的連續性。

透過深度細分分析，將臨床應用、製造技術、產品形式和機構最終用戶需求連結起來，從而指導可行的商業化策略。

細分市場層面的趨勢分析揭示了不同應用、平台技術、產品形式和終端用戶類別之間存在著不同的商業性和營運重點，這些重點都會影響投資規劃和服務設計。在應用領域，診斷影像檢查仍然是臨床需求的主要來源，而心臟病學、神經病學和腫瘤學等亞專科的需求模式則影響著示蹤劑的選擇和檢查安排。心臟病學檢查通常需要可預測且頻繁的示踪劑供應以支持負荷成像項目；神經病學工作流程需要具有特定成像窗口的示踪劑用於受體和灌注研究；腫瘤學應用則優先考慮能夠實現病灶定位和分期的示踪劑，這導致對同位素新鮮度和發生器吞吐量的需求各不相同。工業應用需要不同的性能特徵，強調放射化學穩定性和可追溯性，而治療應用則對純度和劑量有嚴格的限制，這會影響生產和品管流程。

區域比較分析突顯了各主要區域在生產能力、法規環境和臨床需求模式方面的差異，這些差異影響診斷同位素的供應。

區域趨勢塑造生產選擇、監管方式和供應鏈結構，進而直接影響供應可用性和臨床應用。在美洲，強勁的臨床需求、集中的科學研究基礎設施以及注重提升國內韌性的政策，正推動對區域生產路徑的投資。同時，醫療保健體系的多樣性導致私立醫院和公立醫療網路在籌資策略上存在顯著差異。這種區域動態既支持大規模生產以促進跨境分銷，也支持照護現場創新以縮短運往高需求臨床中心的前置作業時間。

在診斷同位素生態系統中，競爭定位、技術研發和卓越的物流能力將決定哪些組織能夠獲得長期價值。

在鉬-99和Technetium-99m產業生態系中，各公司之間的競爭主要圍繞著技術差異化、供應可靠性以及製造、分銷和臨床支援服務的整合。領先企業優先投資於能夠減少運輸依賴的生產方式，例如加強區域迴旋加速器網路和發電機組裝能力；而其他企業則致力於提高現有核子反應爐供應鏈的效率。製造商、物流供應商和臨床網路之間的夥伴關係與策略聯盟日益普遍，旨在確保交付時間並提供現場培訓、品質保證和法規支援等附加價值服務。

為製造商、醫療服務提供者和政策制定者提供具體策略和操作指南，以確保可靠的同位素供應並加速臨床應用。

產業領導者應採用組合式生產和採購策略，平衡集中式批量生產能力與分散式按需生產能力，以降低單點故障風險，並提高對臨床計畫的應對力。在需求量大的臨床中心附近投資興建迴旋加速器設施，將有助於縮短週轉時間，實現當日手術；同時，維持發電機持續生產能力，可確保依賴多日洗脫策略的機構的運作連續性。企業應優先考慮模組化投資，以便逐步擴展，並透過遵循可預測的監管路徑來加快產品上市速度。

我們採用嚴謹的多方法研究框架，結合關鍵相關人員對話、技術審查和供應鏈建模，以確保研究結果的可靠性和檢驗。

本分析的調查方法整合了一手和二手證據，並結合技術檢驗和相關人員三​​角測量，以確保獲得可靠的實踐見解。一手研究包括對行業相關人員相關者（包括生產工程師、放射性藥物管理人員、採購負責人、法規事務專業人員和物流運營人員）進行結構化訪談和深入的定性討論，以直接觀察運營挑戰和戰略重點。二手研究包括對技術文獻、監管指南、專利申請和行業期刊進行系統性回顧，以梳理技術和政策趨勢。

摘要強調，協調一致的投資、清晰的監管政策和穩健的營運是實現永續診斷同位素取得的基礎。

確保鉬-99和Technetium-99m的穩定供應對現代診斷醫學至關重要。技術創新、不斷變化的法規以及供應鏈重組之間的協同作用，為價值鏈上的相關人員帶來了機會和責任。替代生產技術和改進的發生器化學成分為供應多元化和降低系統風險提供了有希望的途徑，但要實現這些益處，需要協調一致的投資、清晰的監管和卓越的運作。包括貿易措施和基礎建設資金籌措在內的政策決策，對採購經濟效益和投資獎勵有著直接的影響。這凸顯了採取綜合方法的必要性，該方法既要兼顧產業政策，又要確保患者獲得所需藥物。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依應用分類的鉬-99和Technetium-99m市場

  • 影像檢查
    • 心臟病學
    • 神經病學
    • 腫瘤學
  • 工業應用
  • 治療用途

9. 依來源分類的鉬-99和Technetium-99m市場

  • 迴旋加速器
  • 核子反應爐

10. 依產品類型分類的鉬-99和Technetium-99m市場

  • 散裝鉬 99
  • 直接生產
  • 發電機
    • 氧化鋁柱
    • 凝膠發生器

11. 依最終用戶分類的鉬-99和Technetium-99m市場

  • 診斷檢查室
    • 醫院檢查室
    • 獨立檢驗機構
  • 醫院
  • 研究所
    • 政府機構
    • 大學

12. 鉬-99和Technetium-99m市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 按組別分類的鉬-99和Technetium-99m市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國鉬-99和Technetium-99m市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國鉬-99和Technetium-99m市場

16. 中國鉬-99和Technetium-99m市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • BWX Technologies, Inc.
  • Cardinal Health, Inc.
  • Curium US LLC
  • GE HealthCare Technologies Inc.
  • IRE NV
  • Jubilant DraxImage Inc.
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt Pharmaceuticals plc
  • NorthStar Medical Radioisotopes, LLC
  • NTP Radioisotopes SOC Ltd
  • SHINE Technologies, Inc.
  • Siemens Healthineers AG
Product Code: MRR-7A380DA7C318

The Molybdenum-99 & Technetium-99m Market was valued at USD 3.55 billion in 2025 and is projected to grow to USD 3.70 billion in 2026, with a CAGR of 6.48%, reaching USD 5.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.55 billion
Estimated Year [2026] USD 3.70 billion
Forecast Year [2032] USD 5.51 billion
CAGR (%) 6.48%

An authoritative overview framing molybdenum-99 and technetium-99m as essential, technically complex pillars of modern diagnostic imaging and clinical workflows

Molybdenum-99 and its decay product technetium-99m remain cornerstones of contemporary nuclear medicine, underpinning a vast swath of diagnostic imaging procedures and supporting certain therapeutic pathways. Technetium-99m's favorable physical properties, including its short half-life and ideal gamma emission, make it uniquely suited for single photon emission imaging across cardiology, neurology, and oncology, while the parent isotope molybdenum-99 serves as the primary source for distribution models that enable widespread clinical access. Beyond clinical diagnostics, these radionuclides find application in industrial settings and research contexts, where radiotracers and imaging agents support material testing, process optimization, and experimental investigations into new radiopharmaceuticals.

The production landscape for these isotopes is technically complex and capital-intensive, spanning reactor-based fission routes and accelerator or cyclotron pathways that directly produce technetium-99m or precursor isotopes. The downstream ecosystem encompasses bulk isotope suppliers, generator manufacturers that convert molybdenum-99 into clinically usable technetium-99m, and a network of diagnostic laboratories, hospitals, and research institutions that manage cold-chain logistics and clinical administration. Regulatory oversight at national and international levels governs radiological safety, transport, and clinical use, while quality management systems ensure consistent specific activity, purity, and sterility of radiopharmaceutical products.

This report synthesizes technical, regulatory, and supply chain considerations to inform strategic choices by manufacturers, healthcare providers, and policymakers. It examines production technologies, generator designs, clinical utilization patterns across major diagnostic specialties, and evolving supply chain risks and mitigations. The analysis highlights where investment, policy alignment, and operational innovation can reduce systemic fragility and support resilient access to critical diagnostic isotopes.

How technological, regulatory, and supply chain innovations have together reshaped production pathways and clinical workflows for diagnostic radionuclides

Over the past decade the molybdenum-99 and technetium-99m ecosystem has experienced several transformative shifts that reshape production, distribution, and clinical usage patterns. Technological innovation has accelerated the adoption of alternative production pathways, including direct cyclotron production of technetium-99m and low-enrichment or non-fission reactor approaches, which reduce reliance on a small set of aging research reactors and improve regulatory acceptability. Concurrently, generator technology has evolved with refinements in column chemistry and gel formulations that aim to enhance elution efficiency, reduce aluminium breakthrough, and simplify on-site handling, thereby shortening preparation timelines for clinical teams.

Supply chain resilience has become a strategic priority for healthcare systems and governments alike, prompting investments in domestic capacity, redundancy across sources, and improvements in cold-chain logistics. Regulatory frameworks have responded by streamlining pathways for alternative production technologies while reinforcing quality and safety requirements, creating clearer pathways for commercialization but also imposing rigorous validation standards. Clinical practice has adapted to these technical and regulatory changes, with nuclear medicine departments optimizing scheduling, radiopharmacy throughput, and tracer selection to align with variable delivery windows and generator performance.

Finally, the broader healthcare and policy landscape has elevated the strategic significance of secure isotope supply as a component of national health resilience. This change has translated into novel funding models, public-private partnerships, and cross-sector collaborations that link industrial capability with clinical demand. The cumulative effect of these trends is a more diversified technology base and a heightened focus on interoperability between producers, distributor networks, and clinical end users, which together underpin a more adaptive and technology-driven supply model for diagnostic radionuclides.

Assessing the systemic effects of 2025 tariff measures on procurement, manufacturing investment, and clinical continuity in the diagnostic isotope supply chain

United States tariff measures introduced in 2025 have exerted a multifaceted influence on the global supply chain for molybdenum-99 and technetium-99m, with implications that ripple across procurement strategies, manufacturing economics, and clinical operations. Tariffs that affect imported production inputs, generator components, and finished isotope consignments create immediate cost pressures for organizations that rely on cross-border supply relationships. In response, stakeholders have accelerated efforts to diversify sourcing, prioritize domestic production pathways, and renegotiate long-term procurement contracts to secure continuity of supply under more predictable total landed cost frameworks.

Tariff impacts extend beyond direct cost increases; they influence investment calculus for both incumbent producers and potential entrants. Higher import duties on critical components for generators, column materials, or specialized transport packaging can lengthen payback periods for new manufacturing facilities and may shift capital toward locally producible technologies such as cyclotron systems and generator assembly lines. This reallocation of capital has the potential to catalyze regional manufacturing clusters that reduce cross-border dependencies, yet it also introduces timing mismatches as new capacity requires regulatory approvals and workforce training before it can alleviate short-term supply constraints.

Clinically, tariff-driven cost dynamics can translate into tighter operating margins for hospital radiopharmacies and independent diagnostic laboratories, prompting workflow adaptations that prioritize high-value procedures and optimize tracer utilization. Procurement teams increasingly evaluate total cost of ownership, factoring in tariff exposure, logistics complexity, and supplier redundancy when structuring contracts. On a policy level, tariffs have prompted dialog between public health authorities and trade negotiators to balance industrial policy objectives with the imperative of uninterrupted access to essential medical isotopes. In parallel, industry consortia and supply chain partners have intensified collaboration to streamline certificate of origin documentation, harmonize customs procedures, and leverage bonded logistics solutions to mitigate tariff impacts.

Overall, the 2025 tariff environment functions as a catalyst for supply chain reconfiguration: it accelerates localization trends, sharpens focus on technology choices that reduce import intensity, and compels healthcare buyers to adopt more sophisticated procurement strategies that integrate tariff risk into resilience planning. While tariffs can impose short-term friction, they also incentivize investments that, if well coordinated, may strengthen long-term supply stability and align production capacity more closely with national clinical needs.

Deep segmentation analysis linking clinical applications, production technologies, product formats, and institutional end-user needs to actionable commercialization strategies

Segment-level dynamics reveal distinct commercial and operational priorities across applications, source technologies, product forms, and end-user categories, each with implications for investment and service design. In terms of application, diagnostic imaging remains the dominant clinical driver with sub-specialty demand patterns in cardiology, neurology, and oncology shaping tracer selection and scheduling practices; cardiology procedures often demand predictable, high-frequency deliveries to support stress imaging programs, neurology workflows require tracers with specific imaging windows for receptor and perfusion studies, and oncology applications prioritize agents that enable lesion localization and staging, creating divergent requirements for isotope freshness and generator throughput. Industrial applications demand different performance characteristics, emphasizing radiochemical robustness and traceability, while therapeutic applications impose rigorous purity and dosing constraints that influence production and quality control processes.

When viewed by source, the industry bifurcates between cyclotron and reactor pathways, with cyclotron approaches offering geographically distributed, on-demand production that reduces transport time and radiological decay losses, and reactor-based production providing high-volume bulk quantities that feed generator supply chains. Each source route influences logistics and regulatory strategy: cyclotron facilities necessitate local technical expertise and maintenance ecosystems, while reactor-sourced supply depends on long-range transport, packaging regulations, and international collaboration.

Product type segmentation further differentiates market behavior. Bulk molybdenum-99 serves as the feedstock for traditional generator models and is subject to long-lead manufacturing and transport considerations. Direct production methods that bypass molybdenum intermediates alter the downstream value chain by enabling point-of-care technetium supply but require different regulatory dossiers and local infrastructure. Generator products themselves are subdivided by chemistry and form factor; alumina column designs represent a long-standing, widely deployed approach with predictable elution profiles, whereas gel generators present opportunities for simplified handling and potential improvements in elution efficiency, each demanding distinct manufacturing controls and user training.

End-user segmentation emphasizes how clinical and institutional structures shape demand and procurement. Diagnostic laboratories-whether hospital based or independent-operate on tight timelines and must balance throughput with regulatory compliance and staff competencies. Hospitals, split between private and public models, exhibit different budgetary constraints and procurement cycles that affect their willingness to invest in on-site cyclotrons or multi-day generator strategies. Research institutes, whether government laboratories or universities, often prioritize experimental flexibility and trace isotope types for development work, necessitating bespoke sourcing arrangements and collaborative agreements with producers. Understanding these intersecting segmentation axes is critical for manufacturers and service providers designing product portfolios, commercial terms, and support services that align with end-user capabilities and clinical workflows.

Comparative regional analysis revealing how production capacity, regulatory environments, and clinical demand patterns shape secured access to diagnostic isotopes across major world regions

Regional dynamics shape production choices, regulatory approaches, and supply chain architectures in ways that directly affect availability and clinical adoption. In the Americas, strong clinical demand, concentrated research infrastructure, and policy interest in domestic resilience have driven investments in localized production pathways, while diverse healthcare systems mean procurement strategies vary significantly between private hospitals and public health networks. This regional profile supports both large-scale production that feeds cross-border distribution and point-of-care innovations that reduce transport lead times for high-volume clinical centers.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and production capabilities. Several nations within this region have longstanding reactor capacity alongside emerging accelerator initiatives, creating a hybrid supply matrix. Regulatory harmonization efforts in parts of the region aim to simplify cross-border distribution and mutual recognition of quality standards, yet logistical complexity and variable infrastructure across countries necessitate tailored distribution and contingency planning. In some jurisdictions, strategic stockholding and intergovernmental agreements have been deployed to buffer short-term disruptions and ensure continued access for high-priority clinical services.

Asia-Pacific demonstrates rapid adoption of alternative production technologies and ambitious expansion of cyclotron networks to meet dense urban demand centers. Robust manufacturing ecosystems for medical devices and radiopharmacy components support local production scaling, while policy focus on domestic industrial capability encourages public-sector investment in isotope infrastructure. Clinical adoption patterns in the region often emphasize procedural volume and throughput optimization, making reliable, frequent deliveries and efficient generator solutions particularly valuable. Across all regions, differences in regulatory timelines, transport logistics, and financing models drive variation in how producers and healthcare providers approach strategic investment and operational design.

How competitive positioning, technological R&D, and logistics excellence determine which organizations capture long-term value in the diagnostic isotope ecosystem

Competitive dynamics among firms operating in the molybdenum-99 and technetium-99m ecosystem revolve around technological differentiation, supply reliability, and the integration of manufacturing with distribution and clinical support services. Leading organizations prioritize investments in production modalities that lower transport dependencies, such as regional cyclotron networks and enhanced generator assembly capabilities, while others pursue efficiency gains within existing reactor-based supply chains. Partnerships and strategic alliances between manufacturers, logistics providers, and clinical networks are increasingly common as companies seek to guarantee delivery windows and provide value-added services such as on-site training, quality assurance, and regulatory support.

R&D intensity centers on generator chemistry improvements and production process optimization that can reduce waste, shorten preparation times, and improve elution yields. Firms that invest in advanced quality management and digital traceability systems are better positioned to meet stringent regulatory expectations and customer demands for transparency. Commercial strategies reflect a dual imperative: secure long-term supply contracts with large hospital systems and establish flexible offerings for smaller diagnostic laboratories that require just-in-time deliveries. This bifurcated approach supports revenue stability while enabling penetration into emerging markets where on-demand production models may be more commercially attractive.

Operational excellence in logistics and cold chain management remains a critical differentiator. Companies that achieve high fulfillment reliability through robust packaging, customs expertise, and contingency routing create tangible clinical value by minimizing procedure cancellations and improving scheduling predictability. As capital flows to new production capacity and generator innovation, the ability to navigate regulatory approvals, scale manufacturing, and sustain quality at volume will determine which firms capture long-term adoption across clinical and research segments.

Actionable strategic and operational directives for manufacturers, healthcare providers, and policymakers to secure reliable isotope supply and accelerate clinical adoption

Industry leaders should adopt a portfolio approach to production and sourcing that balances centralized bulk capacity with decentralized, on-demand capabilities to reduce single-point vulnerabilities and improve responsiveness to clinical schedules. Investing in cyclotron capacity in proximity to high-volume clinical centers will shorten delivery windows and support same-day procedures, while continued stewardship of generator manufacturing capabilities ensures continuity for facilities that rely on multi-day elution strategies. Firms should prioritize modular investments that can be scaled incrementally and that align with foreseeable regulatory pathways to accelerate time-to-market.

Strengthening relationships with regulatory authorities and participating in harmonization initiatives can accelerate approvals for alternative production technologies and new generator chemistries. Proactive engagement reduces uncertainty and enables companies to shape standards that balance innovation with patient safety. At the procurement level, healthcare providers should integrate tariff risk and supply chain resilience into contracting strategies, favoring agreements that include redundancy provisions, flexible delivery terms, and performance guarantees. Cross-sector collaboration, including public-private partnerships, can mobilize funding for critical infrastructure while aligning public health objectives with commercial incentives.

Operationally, organizations must elevate quality assurance, workforce training, and digital traceability. Investing in training programs for radiopharmacy technicians and logistics personnel mitigates risks associated with new generator types and on-site production equipment. Implementing end-to-end digital tracking for batch identity, temperature control, and chain-of-custody increases transparency and supports rapid incident response. Finally, sustainability and environmental compliance should inform capital projects and operational upgrades, as responsible waste management and energy efficiency create social license and reduce long-term operational costs.

A rigorous, multi-method research framework combining primary stakeholder engagement, technical review, and supply chain modeling to ensure reliable, verifiable insights

The research methodology underpinning this analysis integrates primary and secondary evidence with technical validation and stakeholder triangulation to ensure robust, actionable findings. Primary research comprised structured interviews and deeper qualitative discussions with a cross-section of industry participants, including production engineers, radiopharmacy managers, procurement officers, regulatory affairs specialists, and logistics providers, enabling direct observation of operational challenges and strategic priorities. Secondary research involved a systematic review of technical literature, regulatory guidance, patent filings, and trade publications to map technology trajectories and policy developments.

Supply chain mapping and process modeling were employed to assess points of fragility, lead times, and capital intensity across production routes, while scenario analysis evaluated the operational implications of tariff changes, regulatory shifts, and technology adoption. Data quality assurance included cross-validation of interview insights with documentary evidence and anonymized case examples, ensuring that conclusions reflect operational realities rather than isolated perspectives. Limitations of the methodology are acknowledged: proprietary contract terms and non-public production schedules constrain visibility into some supplier behaviors, and rapidly evolving policy environments may alter timelines for infrastructure deployment. To mitigate these constraints, the study emphasizes principles, operational levers, and risk management strategies that remain applicable across differing market circumstances.

Finally, the analysis adheres to ethical research standards with confidentiality protections for interview participants and transparent documentation of sources and assumptions, enabling confidence in the reproducibility and integrity of the findings.

Concluding synthesis emphasizing coordinated investment, regulatory clarity, and operational resilience as the pillars of sustainable diagnostic isotope access

Securing consistent access to molybdenum-99 and technetium-99m is essential for contemporary diagnostic medicine, and the confluence of technological innovation, regulatory evolution, and supply chain realignment offers both opportunities and responsibilities for stakeholders across the value chain. Alternative production technologies and generator chemistry improvements provide credible pathways to decentralize supply and reduce systemic risk, but realizing these benefits requires coordinated investment, regulatory clarity, and operational excellence. Policy decisions, including trade measures and infrastructure funding, have immediate practical consequences for procurement economics and investment incentives, underscoring the need for integrated approaches that balance industrial policy with patient access imperatives.

For manufacturers, the dual focus on technology differentiation and logistical reliability will determine commercial success, while healthcare providers must adapt procurement and clinical workflows to leverage new delivery models. Regulators and policymakers play a critical role in shaping standards that preserve safety while encouraging innovation. In this context, strategic collaboration-whether through public-private partnerships, inter-institutional agreements, or industry consortia-represents the most effective route to build resilient, efficient, and clinically responsive isotope supply systems.

The trajectory ahead is defined by pragmatic choices: prioritize redundancy where risk is intolerable, invest in local capability where clinical demand justifies it, and pursue incremental innovation that reduces handling complexity and enhances clinical value. Stakeholders that act decisively and cooperatively will strengthen the reliability of diagnostic services and support better patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molybdenum-99 & Technetium-99m Market, by Application

  • 8.1. Diagnostic Imaging
    • 8.1.1. Cardiology
    • 8.1.2. Neurology
    • 8.1.3. Oncology
  • 8.2. Industrial Applications
  • 8.3. Therapeutics

9. Molybdenum-99 & Technetium-99m Market, by Source

  • 9.1. Cyclotron
  • 9.2. Reactor

10. Molybdenum-99 & Technetium-99m Market, by Product Type

  • 10.1. Bulk Molybdenum 99
  • 10.2. Direct Production
  • 10.3. Generator
    • 10.3.1. Alumina Column
    • 10.3.2. Gel Generator

11. Molybdenum-99 & Technetium-99m Market, by End User

  • 11.1. Diagnostic Laboratory
    • 11.1.1. Hospital Based Laboratory
    • 11.1.2. Independent Laboratory
  • 11.2. Hospital
  • 11.3. Research Institute
    • 11.3.1. Government Institute
    • 11.3.2. University

12. Molybdenum-99 & Technetium-99m Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Molybdenum-99 & Technetium-99m Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Molybdenum-99 & Technetium-99m Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Molybdenum-99 & Technetium-99m Market

16. China Molybdenum-99 & Technetium-99m Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. BWX Technologies, Inc.
  • 17.6. Cardinal Health, Inc.
  • 17.7. Curium US LLC
  • 17.8. GE HealthCare Technologies Inc.
  • 17.9. IRE NV
  • 17.10. Jubilant DraxImage Inc.
  • 17.11. Lantheus Medical Imaging, Inc.
  • 17.12. Mallinckrodt Pharmaceuticals plc
  • 17.13. NorthStar Medical Radioisotopes, LLC
  • 17.14. NTP Radioisotopes SOC Ltd
  • 17.15. SHINE Technologies, Inc.
  • 17.16. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDUSTRIAL APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDUSTRIAL APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDUSTRIAL APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CYCLOTRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CYCLOTRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CYCLOTRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY BULK MOLYBDENUM 99, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY BULK MOLYBDENUM 99, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY BULK MOLYBDENUM 99, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIRECT PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIRECT PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIRECT PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ALUMINA COLUMN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ALUMINA COLUMN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ALUMINA COLUMN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GEL GENERATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GEL GENERATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GEL GENERATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL BASED LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL BASED LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL BASED LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDEPENDENT LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDEPENDENT LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDEPENDENT LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GOVERNMENT INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GOVERNMENT INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GOVERNMENT INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY UNIVERSITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY UNIVERSITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY UNIVERSITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 156. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 159. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 183. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 186. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 192. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 195. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)